Table 1 Baseline characteristics and medication of the two groups
SCFP group (n = 79) | Control group (n = 158) | P value | |
|---|---|---|---|
Age, years | 61.1 ± 9.0 | 61.1 ± 9.0 | 1 |
Male sex, n (%) | 55(69.6) | 117(74.1) | 0.537 |
BMI | 24.6 ± 2.4 | 23.4 ± 2.8 | 0.001 |
Heart rate | 72.1 ± 11.2 | 72.6 ± 10.8 | 0.752 |
Systolic blood pressure, mmHg | 124.5 ± 18.2 | 123.7 ± 13.1 | 0.691 |
Diastolic pressure, mmHg | 76.3 ± 11.4 | 75.4 ± 8.7 | 0.488 |
Current smoking, n (%) | 20(25.3) | 49(31.0) | 0.448 |
Dyslipidemia, n (%) | 29(36.7) | 33(20.9) | 0.012 |
Hypertension, n (%) | 46(58.2) | 64(40.5) | 0.013 |
Diabetes mellitus, n (%) | 23(29.1) | 26(16.5) | 0.028 |
hyperuricemia, n (%) | 16(20.3) | 25(15.8) | 0.467 |
ACEI/ARB/ARNI, n (%) | 18(22.8) | 32(20.3) | 0.736 |
Beta-blocker, n (%) | 15(19.0) | 28(17.7) | 0.859 |
Calcium canal blocker, n (%) | 22(27.8) | 31(19.6) | 0.186 |
Antiplatelet, n (%) | 16(20.3) | 34(21.5) | 0.867 |
Statin, n (%) | 23(29.1) | 48(30.4) | 0.881 |
Nitrates, n (%) | 24(30.4) | 40(25.3) | 0.440 |